Breaking
🇺🇸 FDA

Latest News

FDA Approves First Interchangeable Humira Biosimilar: Key Details
NewsImmunologyMar 31, 2026

FDA Approves First Interchangeable Humira Biosimilar: Key Details

The FDA has approved the first interchangeable biosimilar to Humira, a significant milestone for patients with autoimmune conditions seeking affordable treatment alternatives.

Dr. Sarah Mitchell
FDA Approves Gilead's Long-Acting HIV Treatment for Bi-Monthly Dosing
NewsHIV/AIDSMar 31, 2026

FDA Approves Gilead's Long-Acting HIV Treatment for Bi-Monthly Dosing

Gilead's long-acting HIV treatment has received FDA approval for bi-monthly dosing, providing patients with a more convenient and effective management option.

Dr. Sarah Mitchell
FDA Grants Priority Review to AstraZeneca's Wilson Disease Treatment
NewsRare DiseasesMar 31, 2026

FDA Grants Priority Review to AstraZeneca's Wilson Disease Treatment

AstraZeneca's innovative treatment for Wilson Disease has received priority review from the FDA, potentially transforming care for patients with this copper metabolism disorder.

Dr. Sarah Mitchell
FDA Grants Accelerated Approval to Eli Lilly's Donanemab for Alzheimer's
NewsNeurologyMar 31, 2026

FDA Grants Accelerated Approval to Eli Lilly's Donanemab for Alzheimer's

Eli Lilly's Donanemab receives accelerated FDA approval for Alzheimer's, offering new hope for patients and families affected by this challenging disease.

Dr. Sarah Mitchell
FDA Approves Novartis' Novel Breast Cancer Drug in Landmark Decision
NewsOncologyMar 31, 2026

FDA Approves Novartis' Novel Breast Cancer Drug in Landmark Decision

In a landmark decision, the FDA has approved Novartis' innovative breast cancer drug, marking a significant advancement in treatment options for patients.

Dr. Sarah Mitchell
FDA Approves Breakthrough KRAS Inhibitor Lumakras for Lung Cancer
NewsoncologyMar 30, 2026

FDA Approves Breakthrough KRAS Inhibitor Lumakras for Lung Cancer

The FDA has approved Lumakras, a groundbreaking KRAS inhibitor, providing a new targeted therapy option for patients battling lung cancer.

Dr. Sarah Mitchell
FDA Approves Talvey (talquetamab) for Relapsed Multiple Myeloma
NewsOncologyMar 30, 2026

FDA Approves Talvey (talquetamab) for Relapsed Multiple Myeloma

The FDA has granted approval for Talvey (talquetamab), a groundbreaking treatment option for patients with relapsed multiple myeloma, enhancing therapeutic choices.

Dr. Sarah Mitchell